Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18426437 | 1.00 | CTSV (0.53) | CTSVCTSLMEN1KMT2AHPGD | |
| SCHEMBL30443242 | 1.00 | CTSV (0.53) | CTSVCTSLMEN1KMT2AHPGD | |
| SCHEMBL1318112 | 0.86 | MEN1 (0.56) | CTSVCTSLMEN1KMT2AHPGD | |
| SCHEMBL20521874 | 0.84 | KDM1A (0.48) | SMN1; SMN2MAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL30221893 | 0.84 | KDM1A (0.48) | SMN1; SMN2MAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL416139 | 0.84 | KDM1A (0.48) | SMN1; SMN2MAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL21835674 | 0.83 | MRGPRX4 (0.53) | SMN1; SMN2MAPTL3MBTL1RAB9A | |
| SCHEMBL20562352 | 0.83 | MEN1 (0.54) | CTSVCTSLMEN1KMT2AHPGD | |
| SCHEMBL4596187 | 0.83 | MEN1 (0.54) | CTSVCTSLMEN1KMT2AHPGD | |
| SCHEMBL20456326 | 0.83 | MEN1 (0.54) | CTSVCTSLMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122182-A1 | MYST Inhibitors | Isosterix, Inc. | 2025-04-17 | — | — | US | disclosed |
| CN-116848100-A | NOTCH inhibitors and uses thereof | 干细胞协同疗法有限责任公司 | 2023-10-03 | — | — | CN | disclosed |
| US-20230183215-A1 | Notch Inhibitors and Uses Thereof | STEMSYNERGY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183215-A1 | Notch Inhibitors and Uses Thereof | STEMSYNERGY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183215-A1 | Notch Inhibitors and Uses Thereof | STEMSYNERGY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| EP-4153575-A1 | NOTCH INHIBITORS AND USES THEREOF | StemSynergy Therapeutics, Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| WO-2021237111-A1 | NOTCH INHIBITORS AND USES THEREOF | STEMSYNERGY THERAPEUTICS, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021237111-A1 | NOTCH INHIBITORS AND USES THEREOF | STEMSYNERGY THERAPEUTICS, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| CN-101889002-A | Be used for preparation at L-3,4-dihydroxyl-6-[ 18F] fluoro-phenylalanine and 2-[ 18F] method of precursor of fluoro-L-tyrosine and their alpha-methylated derivative, precursor and by described precursor preparation L-3,4-dihydroxyl-6-[ 18F] fluoro-phenylalanine and 2-[ 18F] method of fluoro-L-tyrosine and their alpha-methylated derivative | FORSCHUNGSZENTRUM JUELICH GMBH | 2010-11-17 | — | — | CN | disclosed |
| WO-2008099020-A1 | 1,1-DIOXO-1-THIA-5,10-DIAZADIBENZOCYCLOHEPTENES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008099020-A1 | 1,1-DIOXO-1-THIA-5,10-DIAZADIBENZOCYCLOHEPTENES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122182-A1 | MYST Inhibitors | MNAT1, SUGT1, ACAT2 | CTSV 2977/4885CTSL 3045/4885MEN1 487/4885 |
| US-20230183215-A1 | Notch Inhibitors and Uses Thereof | NOTCH1, NOTCH2, NOTCH4 | CTSV 941/4885CTSL 355/4885MEN1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.